The Value of Automated Diabetic Retinopathy Screening with the EyeArt System: A Study of More Than 100,000 Consecutive Encounters from People with Diabetes.

Abstract:

: Background: Current manual diabetic retinopathy (DR) screening using eye care experts cannot scale to screen the growing population of diabetes patients who are at risk for vision loss. EyeArt system is an automated, cloud-based artificial intelligence (AI) eye screening technology designed to easily detect referral-warranted DR immediately through automated analysis of patient's retinal images. Methods: This retrospective study assessed the diagnostic efficacy of the EyeArt system v2.0 analyzing 850,908 fundus images from 101,710 consecutive patient visits, collected from 404 primary care clinics. Presence or absence of referral-warranted DR (more than mild nonproliferative DR [NPDR]) was automatically detected by the EyeArt system for each patient encounter, and its performance was compared against a clinical reference standard of quality-assured grading by rigorously trained certified ophthalmologists and optometrists. Results: Of the 101,710 visits, 75.7% were nonreferable, 19.3% were referable to an eye care specialist, and in 5.0%, the DR level was unknown as per the clinical reference standard. EyeArt screening had 91.3% (95% confidence interval [CI]: 90.9-91.7) sensitivity and 91.1% (95% CI: 90.9-91.3) specificity. For 5446 encounters with potentially treatable DR (more than moderate NPDR and/or diabetic macular edema), the system provided a positive "refer" output to 5363 encounters achieving sensitivity of 98.5%. Conclusions: This study captures variations in real-world clinical practice and shows that an AI DR screening system can be safe and effective in the real world. This study demonstrates the value of this easy-to-use, automated tool for endocrinologists, diabetologists, and general practitioners to address the growing need for DR screening and monitoring.

journal_name

Diabetes Technol Ther

authors

Bhaskaranand M,Ramachandra C,Bhat S,Cuadros J,Nittala MG,Sadda SR,Solanki K

doi

10.1089/dia.2019.0164

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

635-643

issue

11

eissn

1520-9156

issn

1557-8593

journal_volume

21

pub_type

杂志文章
  • Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting.

    abstract::Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have be...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2017.0054

    authors: Schnell O,Barnard K,Bergenstal R,Bosi E,Garg S,Guerci B,Haak T,Hirsch IB,Ji L,Joshi SR,Kamp M,Laffel L,Mathieu C,Polonsky WH,Snoek F,Home P

    更新日期:2017-07-01 00:00:00

  • Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study.

    abstract:BACKGROUND:This study evaluated whether education and use of the advanced meter features of the CONTOUR(®) (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY) blood glucose monitoring system (BGMS) affect the frequency and pattern of blood glucose testing in insulin-using subjects with diabetes who routinely perform s...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2012.0051

    authors: Bergenstal RM,Bode BW,Tamler R,Trence DL,Stenger P,Schachner HC,Fullam J,Pardo S,Kohut T,Fisher WA

    更新日期:2012-10-01 00:00:00

  • High Glucose Variability in Hospitalized Patients with Type 1 Diabetes Mellitus.

    abstract:BACKGROUND:Glucose variability (GV) has been increasingly (or more extensively) studied in patients with type 1 diabetes (T1D) in the ambulatory setting; limited data exist on GV in hospitalized patients with T1D. MATERIALS AND METHODS:Retrospective single center cohort study, we analyzed in-hospital glucose measureme...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2017.0107

    authors: Dadlani V,Tamhane SU,Sun A,Sharma A,Delivanis DA,Thapa P,Carter RE,Kudva YC

    更新日期:2017-10-01 00:00:00

  • Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type 1 Diabetes.

    abstract:: Objective: To assess the safety and efficacy of a simplified initialization for the Tandem t:slim X2 Control-IQ hybrid closed-loop system, using parameters based on total daily insulin ("MyTDI") in adolescents with type 1 diabetes under usual activity and during periods of...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0471

    authors: Schoelwer MJ,Robic JL,Gautier T,Fabris C,Carr K,Clancy-Oliveri M,Brown SA,Anderson SM,DeBoer MD,Cherñavvsky DR,Breton MD

    更新日期:2020-08-01 00:00:00

  • The StatStrip glucose monitor is suitable for use during hyperinsulinemic euglycemic clamps in a pediatric population.

    abstract:BACKGROUND:The hyperinsulinemic euglycemic clamp is the gold standard for assessment of insulin resistance and requires frequent, accurate measurements of blood glucose concentrations, typically utilizing the YSI 2300 STAT Plus™ glucose analyzer (YSI, Inc., Yellow Springs, OH). Despite its accuracy, the YSI has several...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2013.0288

    authors: Lindquist KA,Chow K,West A,Pyle L,Isbell TS,Cree-Green M,Nadeau KJ

    更新日期:2014-05-01 00:00:00

  • Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.

    abstract::This study was designed to determine plasma glucose and insulin levels after administration of three escalating doses of the oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in fasting, insulin-deprived adult patients with type 1 diabetes. The study was also designed to assess the safety of the product. Sixte...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091502760306544

    authors: Clement S,Still JG,Kosutic G,McAllister RG

    更新日期:2002-01-01 00:00:00

  • The emergence of biosimilar insulin preparations--a cause for concern?

    abstract::Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture "copies" commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2012.0105

    authors: Owens DR,Landgraf W,Schmidt A,Bretzel RG,Kuhlmann MK

    更新日期:2012-11-01 00:00:00

  • Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin.

    abstract:AIMS:This study compared glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes mellitus (T1DM) treated with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) using regular (RI) or lispro (LP) insulin. METHODS:Three hundred fifteen consecutive singleton...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0111

    authors: Chico A,Saigi I,García-Patterson A,Santos MD,Adelantado JM,Ginovart G,de Leiva A,Corcoy R

    更新日期:2010-12-01 00:00:00

  • Daily glucose profiles in Japanese people with normal glucose tolerance as assessed by continuous glucose monitoring.

    abstract:BACKGROUND:Little information is available regarding glucose fluctuations in postprandial states and during the oral glucose tolerance test (OGTT) in Japanese people with normal glucose tolerance (NGT). METHODS:Glucose profiles of 27 Japanese people were measured for 4 days by using continuous glucose monitoring. A 75...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0083

    authors: Tsujino D,Nishimura R,Taki K,Miyashita Y,Morimoto A,Tajima N

    更新日期:2009-07-01 00:00:00

  • Development of optimal kids insulin dosing system formulas for young children with type 1 diabetes mellitus.

    abstract:OBJECTIVE:This study was designed to develop predictive formulas for precise insulin dosing in young children with type 1 diabetes (T1DM). RESEARCH DESIGN AND METHODS:Consecutive 1-year data from a group of 14 young patients (eight girls, six boys) 3.9 ± 0.8 years old with diabetes duration of 2.0 ± 0.8 years, transit...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0184

    authors: Alemzadeh R,Hoffmann RG,Dasgupta M,Parton E

    更新日期:2012-05-01 00:00:00

  • Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.

    abstract::Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class, albiglutide, liraglutide, dulaglutide, and semaglutide, also have cardioprotective effects. However, subcutaneous administration of these agents...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2019.0185

    authors: Bucheit JD,Pamulapati LG,Carter N,Malloy K,Dixon DL,Sisson EM

    更新日期:2020-01-01 00:00:00

  • Real-time adaptive models for the personalized prediction of glycemic profile in type 1 diabetes patients.

    abstract:BACKGROUND:Prediction of glycemic profile is an important task for both early recognition of hypoglycemia and enhancement of the control algorithms for optimization of insulin infusion rate. Adaptive models for glucose prediction and recognition of hypoglycemia based on statistical and artificial intelligence technique...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0093

    authors: Daskalaki E,Prountzou A,Diem P,Mougiakakou SG

    更新日期:2012-02-01 00:00:00

  • Skin autofluorescence and complications of diabetes: does ethnic background or skin color matter?

    abstract:AIMS:Skin autofluorescence (AF) has been associated with complications of diabetes. We evaluated the influence of skin color and ethnicity on the association between skin AF and the presence of diabetes-related complications. MATERIALS AND METHODS:In a multiethnic type 2 diabetes cohort we investigated all patients wi...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2013.0374

    authors: Ahdi M,Gerdes VE,Graaff R,Kuipers S,Smit AJ,Meesters EW

    更新日期:2015-02-01 00:00:00

  • Inaccurate Glucose Sensor Values After Hydroxyurea Administration.

    abstract:: Objective: To assess the degree, duration, mean absolute relative difference (MARD), and error analysis of discrepant values per continuous glucose monitoring (CGM) systems after hydroxyurea (HU) administration. Research Design and Methods: ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0490

    authors: Tellez SE,Hornung LN,Courter JD,Abu-El-Haija M,Nathan JD,Lawson SA,Elder DA

    更新日期:2020-12-30 00:00:00

  • Incidence and Predictors of Dysglycemia and Regression to Normoglycemia in Indian Adolescents and Young Adults: 10-Year Follow-Up of the ORANGE Study.

    abstract:: Background: The prevalence of diabetes in youth is increasing worldwide in parallel with the obesity epidemic. This study aimed to determine the incidence rates of dysglycemia (diabetes or prediabetes) and evaluate the predictors of its progression or regression to normal ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0109

    authors: Mehreen TS,Kamalesh R,Pandiyan D,Kumar DS,Anjana RM,Mohan V,Ranjani H

    更新日期:2020-12-01 00:00:00

  • The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study.

    abstract:BACKGROUND:The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:Patients with glycated hemoglobin (HbA1c) levels of ≥8% (64 mmol/mol) and...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2015.0159

    authors: Conget I,Castaneda J,Petrovski G,Guerci B,Racault AS,Reznik Y,Cohen O,Runzis S,de Portu S,Aronson R,OpT2mise Study Group.

    更新日期:2016-01-01 00:00:00

  • Nocturnal continuous glucose monitoring: accuracy and reliability of hypoglycemia detection in patients with type 1 diabetes at high risk of severe hypoglycemia.

    abstract:BACKGROUND:A reliable method to detect biochemical nocturnal hypoglycemia is highly needed, especially in patients with recurrent severe hypoglycemia. We evaluated reliability of nocturnal continuous glucose monitoring (CGM) in patients with type 1 diabetes at high risk of severe hypoglycemia. PATIENTS AND METHODS:Sev...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2013.0004

    authors: Bay C,Kristensen PL,Pedersen-Bjergaard U,Tarnow L,Thorsteinsson B

    更新日期:2013-05-01 00:00:00

  • Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes.

    abstract:BACKGROUND:Improved insulin infusion set survival and faster insulin action are important issues for pump users and for the development of an artificial pancreas. The current recommendation is to change infusion sets every 3 days. Our objectives were to determine the effect of lipohypertrophy (LH) on infusion set survi...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2015.0432

    authors: Karlin AW,Ly TT,Pyle L,Forlenza GP,Messer L,Wadwa RP,DeSalvo DJ,Payne SL,Hanes S,Clinton P,Maahs DM,Buckingham B

    更新日期:2016-07-01 00:00:00

  • An intelligent diabetes software prototype: predicting blood glucose levels and recommending regimen changes.

    abstract::Maintaining optimal blood glucose (BG) control is difficult for type 1 diabetes mellitus (T1DM) patients when typical daily regimens of food, insulin and exercise are altered. Artificial intelligence (AI) systems consisting of treatment algorithms calibrated through large datasets of patient specific information may o...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/15209150050501989

    authors: Otto E,Semotok C,Andrysek J,Basir O

    更新日期:2000-01-01 00:00:00

  • Perioperative Characteristics of the Accuracy of Subcutaneous Continuous Glucose Monitoring: Pilot Study in Neurosurgery and Cardiac Surgery.

    abstract:BACKGROUND:The aim of this study was to elucidate the characteristics of accuracy of subcutaneous continuous glucose monitoring (SCGM) in the perioperative period for neurosurgical and cardiac surgery patients. METHODS:Forty-five subjects, including healthy volunteers (n = 15), neurosurgical patients (n = 15), and car...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0140

    authors: Sugiyama Y,Wakabayashi R,Urasawa M,Maruyama Y,Shimizu S,Kawamata M

    更新日期:2018-10-01 00:00:00

  • Evaluating rate of change as an index of glycemic variability, using continuous glucose monitoring data.

    abstract:BACKGROUND:There is no consensus as to the best method to assess glycemic variability from continuous glucose monitoring (CGM) data. Rate of change has been suggested as a preferred method of assessing glycemic variability, but this assertion has not been validated. METHODS:Forty-eight hours of CGM data were analyzed ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2010.0215

    authors: Whitelaw BC,Choudhary P,Hopkins D

    更新日期:2011-06-01 00:00:00

  • Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.

    abstract:BACKGROUND:Drugs with unspecific stimulating effects on beta-cell secretion increase the homeostasis model assessment (HOMA)-B score, indicating improved beta-cell "function." We investigated whether the beta-cell protection provided by adding pioglitazone (PIO) to glimepiride (GLIM) in comparison to up-titrating the G...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2010.0019

    authors: Pfützner A,Derwahl M,Jacob S,Hohberg C,Blümner E,Lehmann U,Fuchs W,Forst T

    更新日期:2010-08-01 00:00:00

  • Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.

    abstract:BACKGROUND:Long-term treatment is necessary to slow the progression of type 2 diabetes (T2D). Here, we examined the safety and efficacy of 6 years of treatment with exenatide once weekly (QW) among patients with T2D in the DURATION-1 trial. METHODS:The study enrolled patients aged ≥16 years with T2D treated primarily ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2016.0107

    authors: Henry RR,Klein EJ,Han J,Iqbal N

    更新日期:2016-11-01 00:00:00

  • Clinical Practice Recommendations on the Routine Use of Eversense, the First Long-Term Implantable Continuous Glucose Monitoring System.

    abstract:: Background: The use of real-time continuous glucose monitoring (rtCGM) systems has proved to positively impact the management of type 1 diabetes with the potential to lower HbA1c, reduce frequency and time spent in hypoglycemia, and lower glycemic variability. Nevertheless...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0397

    authors: Deiss D,Szadkowska A,Gordon D,Mallipedhi A,Schütz-Fuhrmann I,Aguilera E,Ringsell C,De Block C,Irace C

    更新日期:2019-05-01 00:00:00

  • Benchmark data from the literature for evaluation of new glucose sensing technologies.

    abstract::New glucose sensors based on various technologies are being developed to provide information for improved therapy in diabetes. There is a need to establish rational performance standards for these sensors. Frequently sampled, direct blood glucose recordings representative of blood glucose excursions in diabetes are th...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/15209150152607196

    authors: Bremer TM,Edelman SV,Gough DA

    更新日期:2001-10-01 00:00:00

  • Variability of insulin absorption and insulin action.

    abstract::Subcutaneous (s.c.) injections of identical insulin doses may lead to considerable intra- and inter-individual differences in the current metabolic control of patients with diabetes mellitus. This well-known variability of the metabolic effect of insulin hampers practical insulin therapy considerably. The aim of this ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/152091502320798312

    authors: Heinemann L

    更新日期:2002-01-01 00:00:00

  • Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.

    abstract:BACKGROUND:Weight gain often occurs when insulin therapy is initiated. The long-acting insulin analog insulin detemir has been shown to be effective and well tolerated when used in basal-bolus regimens or as an add-on to oral antidiabetic drugs (OADs) and causes less weight gain than other insulins. The aim of this exp...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2008.0282

    authors: Davies MJ,Derezinski T,Pedersen CB,Clauson P

    更新日期:2008-08-01 00:00:00

  • Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers.

    abstract::By the year 2030, the diabetes pandemic will likely affect more than 10% of the world's population. The personal, public health, and economic crises implicit in this trend call for decisive action. Yet, escalating dilemmas thwart full realization of current therapies. First, controversial studies, such as the Action t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2012.0132

    authors: Hirsch IB,Amiel SA,Blumer IR,Bode BW,Edelman SV,Seley JJ,Verderese CA,Kilpatrick ES

    更新日期:2012-11-01 00:00:00

  • The Effectiveness of Continuous Glucose Monitoring in Patients with Type 2 Diabetes: A Systematic Review of Literature and Meta-analysis.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) provides glucose trend information that can be used to guide treatment and motivate patients with diabetes. Currently, the evidence on effectiveness of CGM in patients with type 2 diabetes is debatable. We aim to provide a systematic review and meta-analysis to synthesize ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1089/dia.2018.0177

    authors: Park C,Le QA

    更新日期:2018-09-01 00:00:00

  • Virtual Coaching to Enhance Diabetes Care.

    abstract::Rates of diabetes are increasing worldwide and there is not a sufficient clinical workforce to care for these patients. Diabetes-related apps are a feasible way to provide diabetes education to large numbers of people with diabetes but attrition rates are high. Apps enhanced by virtual coaching may be a way to circumn...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2019.0016

    authors: Ramchandani N

    更新日期:2019-06-01 00:00:00